S&P 500   5,258.04 (+0.18%)
DOW   39,823.15 (+0.16%)
QQQ   444.52 (-0.07%)
AAPL   172.11 (-0.69%)
MSFT   421.38 (-0.01%)
META   488.49 (-1.09%)
GOOGL   151.13 (+0.17%)
AMZN   180.58 (+0.42%)
TSLA   175.50 (-2.41%)
NVDA   903.95 (+0.16%)
NIO   4.50 (-3.64%)
AMD   180.16 (+0.32%)
BABA   72.39 (+1.12%)
T   17.67 (+0.68%)
F   13.25 (+1.45%)
MU   117.73 (-1.18%)
CGC   8.49 (-11.10%)
GE   175.94 (-2.32%)
DIS   122.48 (+1.24%)
AMC   3.73 (-14.06%)
PFE   27.84 (+0.22%)
PYPL   66.99 (+0.63%)
XOM   116.31 (+1.17%)
S&P 500   5,258.04 (+0.18%)
DOW   39,823.15 (+0.16%)
QQQ   444.52 (-0.07%)
AAPL   172.11 (-0.69%)
MSFT   421.38 (-0.01%)
META   488.49 (-1.09%)
GOOGL   151.13 (+0.17%)
AMZN   180.58 (+0.42%)
TSLA   175.50 (-2.41%)
NVDA   903.95 (+0.16%)
NIO   4.50 (-3.64%)
AMD   180.16 (+0.32%)
BABA   72.39 (+1.12%)
T   17.67 (+0.68%)
F   13.25 (+1.45%)
MU   117.73 (-1.18%)
CGC   8.49 (-11.10%)
GE   175.94 (-2.32%)
DIS   122.48 (+1.24%)
AMC   3.73 (-14.06%)
PFE   27.84 (+0.22%)
PYPL   66.99 (+0.63%)
XOM   116.31 (+1.17%)
S&P 500   5,258.04 (+0.18%)
DOW   39,823.15 (+0.16%)
QQQ   444.52 (-0.07%)
AAPL   172.11 (-0.69%)
MSFT   421.38 (-0.01%)
META   488.49 (-1.09%)
GOOGL   151.13 (+0.17%)
AMZN   180.58 (+0.42%)
TSLA   175.50 (-2.41%)
NVDA   903.95 (+0.16%)
NIO   4.50 (-3.64%)
AMD   180.16 (+0.32%)
BABA   72.39 (+1.12%)
T   17.67 (+0.68%)
F   13.25 (+1.45%)
MU   117.73 (-1.18%)
CGC   8.49 (-11.10%)
GE   175.94 (-2.32%)
DIS   122.48 (+1.24%)
AMC   3.73 (-14.06%)
PFE   27.84 (+0.22%)
PYPL   66.99 (+0.63%)
XOM   116.31 (+1.17%)
S&P 500   5,258.04 (+0.18%)
DOW   39,823.15 (+0.16%)
QQQ   444.52 (-0.07%)
AAPL   172.11 (-0.69%)
MSFT   421.38 (-0.01%)
META   488.49 (-1.09%)
GOOGL   151.13 (+0.17%)
AMZN   180.58 (+0.42%)
TSLA   175.50 (-2.41%)
NVDA   903.95 (+0.16%)
NIO   4.50 (-3.64%)
AMD   180.16 (+0.32%)
BABA   72.39 (+1.12%)
T   17.67 (+0.68%)
F   13.25 (+1.45%)
MU   117.73 (-1.18%)
CGC   8.49 (-11.10%)
GE   175.94 (-2.32%)
DIS   122.48 (+1.24%)
AMC   3.73 (-14.06%)
PFE   27.84 (+0.22%)
PYPL   66.99 (+0.63%)
XOM   116.31 (+1.17%)
NASDAQ:NUVA

NuVasive (NUVA) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$39.75
$39.75
50-Day Range
$38.12
$40.66
52-Week Range
$35.17
$49.53
Volume
N/A
Average Volume
1.16 million shs
Market Capitalization
$2.08 billion
P/E Ratio
79.50
Dividend Yield
N/A
Price Target
$51.33
NUVA stock logo

About NuVasive Stock (NASDAQ:NUVA)

NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California. As of September 1, 2023, NuVasive, Inc. operates as a subsidiary of Globus Medical, Inc.

NUVA Stock News Headlines

AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Q4 2023 Globus Medical Inc Earnings Call
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Globus lays off Nuvasive employees after merger
SMAIO: 2023 Sales up +120% to €5.4 Million
Nuvasive’s former CEO joins 3M spinoff
Globus Medical Reports Third Quarter 2023 Results
NuVasive Stock Hits New 52-Week Low (NUVA)
See More Headlines
Receive NUVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NuVasive and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/02/2023
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Devices
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:NUVA
CUSIP
67070410
Employees
3,000
Year Founded
1997

Price Target and Rating

Average Stock Price Target
$51.33
High Stock Price Target
$58.00
Low Stock Price Target
$45.00
Potential Upside/Downside
+29.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$40.41 million
Pretax Margin
3.41%

Debt

Sales & Book Value

Annual Sales
$1.23 billion
Cash Flow
$4.96 per share
Book Value
$17.02 per share

Miscellaneous

Free Float
52,171,000
Market Cap
$2.08 billion
Optionable
Optionable
Beta
1.07

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. J. Christopher BarryMr. J. Christopher Barry (Age 50)
    CEO & Director
    Comp: $3.08M
  • Mr. Matthew K. Harbaugh (Age 53)
    Principal Accounting Officer, CFO & Exec. VP
    Comp: $1.37M
  • Mr. Dale A. Wolf (Age 43)
    Sr. VP of Global Operations
    Comp: $782.6k
  • Mr. Nathaniel B. Sisitsky Esq. (Age 48)
    Sr. VP, Gen. Counsel & Corp. Sec.
    Comp: $842.84k
  • Mr. Michael Farrington (Age 39)
    Sr. VP of People & Culture
    Comp: $626.46k
  • Mr. Ryan Donahoe
    Sr. VP & Chief Technology Officer
  • Ms. Juliet C. Cunningham
    VP of Investor Relations
  • Mr. Sean Freeman
    Sr. VP of Strategy & Corp. Devel.
  • Ms. Lisa Pecora
    VP & Head of Global Commercial Fin.
  • Ms. Aviva McPherron
    Sr. VP of Information Technology

NUVA Stock Analysis - Frequently Asked Questions

Should I buy or sell NuVasive stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NUVA shares.
View NUVA analyst ratings
or view top-rated stocks.

What is NuVasive's stock price target for 2024?

2 brokerages have issued twelve-month target prices for NuVasive's stock. Their NUVA share price targets range from $45.00 to $58.00. On average, they predict the company's share price to reach $51.33 in the next twelve months. This suggests a possible upside of 29.1% from the stock's current price.
View analysts price targets for NUVA
or view top-rated stocks among Wall Street analysts.

How were NuVasive's earnings last quarter?

NuVasive, Inc. (NASDAQ:NUVA) issued its quarterly earnings results on Wednesday, August, 2nd. The medical device company reported $0.56 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.56. The medical device company had revenue of $317.80 million for the quarter, compared to the consensus estimate of $322.53 million. NuVasive had a net margin of 2.32% and a trailing twelve-month return on equity of 12.17%. The company's revenue for the quarter was up 2.4% compared to the same quarter last year. During the same period last year, the company earned $0.47 earnings per share.

What is Chris Barry's approval rating as NuVasive's CEO?

59 employees have rated NuVasive Chief Executive Officer Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among the company's employees.

What other stocks do shareholders of NuVasive own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT).

Does NuVasive have any subsidiaries?
The following companies are subsidiares of NuVasive: Biotronic NeuroNetwork, Ellipse Technologies, NuVasive Clinical Services Monitoring Inc., NuVasive Japan KK, NuVasive Specialized Orthopedics Inc., NuVasive Technology International Limited, SafePassage, Simplify Medical, and Vertera Spine.
Read More
This page (NASDAQ:NUVA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners